Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medplus Health Services has informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received three suspension orders for drug licenses of three stores across Karnataka, Telangana, and Andhra Pradesh. The suspensions range from two to seven days, issued by various Assistant Directors of Drugs Control Administration under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined potential revenue loss is around Rs 4.79 lakhs (Rs 1.07 lakh, Rs 1.60 lakh, and Rs 2.12 lakh for the three stores). The orders were received on March 13, 2026. The company has disclosed full details on its website and stock exchange portals as required.
The financial impact is negligible (under Rs 5 lakhs total) and confined to three individual stores, so this is unlikely to materially affect the company's operations or stock price. However, repeated license actions could raise minor compliance scrutiny for the pharmacy chain.